Stroke: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• NLRP3 0
• NRF2 0
• GLP-1 4
• PCSK9 12
• AKT 0
• PI3K 0
• SGLT2 2
• BDNF 2
• TLR4 0
• AMPK 0
• STAT3 0
• mTOR 0
• VEGF 0
• ERK 0
• HIF-1 0
• SIRT1 0
• PPAR 1
• STING 0
• GPX4 0
• MMP-9 0
• HMGB1 0
• IL-6 0
• APOE 0
• JAK 0
• NOTCH3 1
• MAPK 0
• NMDA 0
• TNF 0
• TP53 0
• DPP-4 1
• CTNNB1 0
• CXCR4 0
• IL-1 1
• TREM2 0
• FTO 0
• IL-17 0
• JNK 0
• COX-2 0
• PTEN 0
• PARP 0
• YAP 0
• AQP4 0
• CCR5 1
• BCL-2 0
• EGFR 0
• PINK1 0
• HSP90 0
• AR 0
• GIP 0
• HDAC 0
• PD-L1 0
• PDE4 0
• PDGFR 0
• TFEB 0
• ATM 0
• B7-H3 0
• CGRP 0
• FOXP3 0
• MAPT 0
• MEK 0

8 of 8+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, United States· until Oct 2028

• U.S. Department of Veterans Affairs · IK2

  Remotely administered tDCS to improve cognitive function in Veterans with mTBI and PTSD

  Philadelphia Va Medical Center· Philadelphia, United States· until Sept 2031

• U.S. Department of Veterans Affairs · IK6

  ISRM Research Career Scientist Award Application

  Veterans Health Administration· Pittsburgh, United States· until Sept 2031

• U.S. Department of Veterans Affairs · I01

  Nitrated oleic acid-mediated angiogenesis and long-term functional recovery after ischemic stroke

  Veterans Health Administration· Pittsburgh, United States· until Sept 2030

• NIH NEI · R01

  The role of the ventral visual pathway processes in activities of daily living

  Carnegie-Mellon University· Pittsburgh, United States· US$619,020 awarded in fiscal year 2026· until Jun 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD

  Understanding learning variability to personalise training and boost knowledge-driven, efficient and acceptable neurotechnologies (VARIABILITI)

  Universite de Bordeaux· Bordeaux, France· EU contribution €4,606,137· until Feb 2032· 11 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Supermassive Black Hole Transients: From Single Brush Strokes to the Entire Painting (BHFlares)

  Tel Aviv University· Tel Aviv, Israel· EU contribution €2,053,750· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Human–robot Adaptive Role MOdulation with Neuro-inspired trajectorY (HARMONY)

  Scuola Universitaria Professionale Della Svizzera Italiana· Manno, Switzerland· EU contribution €292,119· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  From lab to life: measuring and modulating musculoskeletal load in human locomotion (MSKLOAD)

  Norges Idrettshogskole· Oslo, Norway· EU contribution €334,273· until Jun 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Emerging risk factors for stroke: Deciphering the biological mechanisms underlying the impact of chronic stress on the microbiome and microglia epigenetics. (MicroStress)

  Ludwig-Maximilians-Universitaet Muenchen· Planegg, Germany· EU contribution €202,125· until Dec 2028

10 of 2,957 running projects, newest first. Listed amounts together: US$1.8bn + €396.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Immunomodulatory Effects of PCSK9 Inhibition

  NCT05720156· Massachusetts General Hospital· Updated 26 Sept 2025

  “Lack of Feasibility”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Novartis Pharmaceuticals· Source

• Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

  NCT04847752· Tongji Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 38
• Organoids 7
• Mendelian Randomization Analysis 168
• CRISPR-Cas Systems 4
• Gene Expression Profiling 74
• Sequence Analysis, RNA 12
• Exome Sequencing 8
• Proteomics 98
• Metabolomics 71
• Mass Spectrometry 12
• Flow Cytometry 12
• Immunohistochemistry 33
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 33
• Magnetic Resonance Imaging 852
• Machine Learning 355
• Deep Learning 123
• Cohort Studies 946
• Genome-Wide Association Study 140

• Discovery of a Novel Anti-Cancer Agent Targeting Both Topoisomerase I & II as Well as Telomerase Activities in Human Lung Adenocarcinoma A549 Cells In Vitro and In Vivo: Cinnamomum verum Component Cuminaldehyde.

  Curr Cancer Drug Targets, Jan 2016

See which targets of this disease your abstract mentions, and go to the people working on them.